Introduction {#S1}
============

The two human γ-herpesviruses Epstein--Barr virus (EBV or HHV4) and Kaposi sarcoma-associated herpesvirus (KSHV or HHV8) are WHO class I carcinogens and responsible for around 10% of the infection-associated tumors in humans ([@B1], [@B2]). Even so they belong to the same subfamily of herpesviruses, their penetration of the human population, oncogenicity, and tissue tropism is quite different. While EBV persistently infects more than 90% of the human adult population, KSHV seropositivity is quite rare in Europe and the USA (\<10%), but approaches 50% in Africa ([@B3]). The endothelial cell-derived Kaposi sarcoma is the only malignancy that is consistently associated with KSHV alone. In addition, KSHV is found in the lymphoproliferation multicentric Castleman's disease, which can progress to non-Hodgkin's lymphoma in the minority of cases ([@B4]), and primary effusion lymphoma (PEL) which in 90% of cases also harbors EBV ([@B5]). In addition to PELs, EBV is also found in various lymphocyte and epithelial cell malignancies, including Burkitt's lymphoma, Hodgkin's lymphoma, diffuse large B cell lymphoma (DLBCL), natural killer (NK)/T cell lymphoma, nasopharyngeal carcinoma, and gastric carcinoma ([@B5]). As already suggested by the breadth of tumors that it is associated with, EBV is also the much more growth-transforming virus of the two, readily immortalizing human B cells into lymphoblastoid cell lines (LCLs) upon infection *in vitro*. Furthermore, EBV is associated with so many different malignancies, because it adjusts its gene expression pattern to the differentiation stages of its main host cell, the human B cell, and thereby contributes to various degrees to the transformation in these different malignancies ([@B6]). The latent infection program with the largest number of expressed proteins is called latency III and is found in naïve B cells of healthy EBV carriers and DLBCL as well as LCL ([@B7]). During latency III, six nuclear proteins (EBNAs), two latent membrane proteins (LMPs), and non-translated miRNAs as well as EBERs are expressed. In latency II of Hodgkin's lymphoma and germinal center B cells of healthy EBV carriers only EBNA1, the two LMPs and the non-translated RNAs are expressed. Finally, in latency I of Burkitt's lymphoma and homeostatically dividing memory B cells, only EBNA1 and the non-translated RNAs are expressed. EBV is thought to persist in resting memory B cells without latent protein expression, only transcribing the non-translated RNAs from episomal viral DNA ([@B8]). Cognate antigen recognition by the B cell receptor is then able to reactivate EBV from this memory pool, and plasma cell differentiation is associated with lytic infectious virus production ([@B9]). Such lytic EBV infection in mucosal epithelia amplifies viral titers once more for shedding into saliva and transmission ([@B10]). In contrast to these distinct EBV infection programs, KSHV gene expression does not seem to be primarily restricted to the latency gene products latency-associated nuclear antigen, viral FLICE inhibitory protein (vFLIP), and viral D-type cyclin (vCyclin) in tumor tissues ([@B5]). Instead, expression of the lytic gene products K1, K2, and K15 seem to support the anti-apoptotic function of vFLIP to ensure survival of KSHV-associated tumor cells, which proliferate in part due to vCyclin expression ([@B11]). KSHV is thought to persist in long-lived plasma cells ([@B12]). How these patterns of viral oncogene expression are coordinated to cause KSHV- and EBV-associated pathogenesis and which immune compartments prevent them in healthy carriers of these human γ-herpesviruses has been difficult to study due to the exclusive tropism of these viruses for humans. With the advent of mice with reconstituted human immune system components (HIS mice), some of these questions can be addressed, and this review summarizes the insights into the fascinating biology of these human tumor viruses that could be gained so far.

EBV and KSHV infection {#S2}
======================

Epstein--Barr virus was one of the first pathogens that HIS mice were challenged with ([@B13]--[@B17]). All programs of EBV infection in B cells were found after intraperitoneal infection of reconstituted NOD-*scid* $\gamma_{\text{c}}^{- / -}$ (NSG), NOD-*scid* $\gamma_{\text{c}}^{\text{truncated}}$ (NOG), BALB/c Rag2^−/−^ $\gamma_{\text{c}}^{- / -}$ (BRG), and human fetal liver plus human fetal thymus transplanted NOD-*scid* (BLT) mice, but latency III predominates ([@B18], [@B19]). Most of these studies found persistence of EBV in HIS mice for several months with circulating total viral loads in the blood of 10^4^ and 10^3^/ml in the serum after 4--5 weeks of infection with 10^5^ viral particles ([@B20], [@B21]). At this time point, total viral loads reach 10^7^ viral DNA copies/g in secondary lymphoid tissues like spleen and lymph nodes. These viral loads are comparable to blood viral loads in patients with symptomatic primary EBV infection, called infectious mononucleosis (IM) ([@B22]) that surprisingly do not differ very much from overall blood viral loads of asymptomatic primary infection ([@B23], [@B24]). In most of these studies, the B95-8 EBV strain was used, which reactivates only very weakly into lytic replication and was originally isolated from an American IM patient ([@B25], [@B26]). Indeed, in a direct comparison of wild-type (wt) and BZLF1-deficient (ZKO) EBV viruses on the B95-8 background viral titer differences were only observed at week three after infection ([@B20]). At this time point, some wt EBV-infected HIS mice reached already 10^4^ DNA copies/ml in the blood, while ZKO EBV-infected mice have 10^3^. These characteristics can be altered by using different viral strains for HIS mouse infection. Infection with 10^5^ B cell infectious particles of the M81 EBV strain, which was isolated from a Chinese nasopharyngeal carcinoma patient, leads to 10^5^--10^6^ DNA copies/ml in the peripheral blood of HIS mice after 4--5 weeks of infection ([@B27]), and other EBV strains fall in between the two extremes of B95-8 and M81 ([@B28]). Thus, EBV infection with 10^5^ infectious viral particles causes a primary EBV infection in HIS mice with similar viral loads that have been reported in human symptomatic and asymptomatic primary infections that can persist for months, even so many HIS mice with such high-persistent viral loads succumb to EBV-induced lymphoproliferations, as discussed below.

Kaposi sarcoma-associated herpesvirus infection of HIS mice on its own is a transient phenomenon with less than 20% of mice maintaining KSHV after infection with 10^5^--10^7^ infectious particles at 5 weeks post infection ([@B29]). However, repeated infections can maintain KSHV for several months in BLT mice on the NSG mouse background, as assessed by expression of KSHV gene products and KSHV-encoded GFP 2 weeks after the final inoculation ([@B30]). However, co-infection with EBV maintains KSHV in the majority of infected HIS mice of the NSG mouse background after single infection ([@B29]). During both transient and persistent KSHV infections, the virus can be found in human B cells ([@B29], [@B30]), and after 5 weeks of double-infection of KSHV with EBV, KSHV is primarily observed in EBV-infected B cells ([@B29]). Double-infection leads to 25% mortality of HIS mice after 5 weeks of infection, while single EBV infection causes much less pathology ([@B29]). These findings suggest that HIS mice can serve as *in vivo* infection models for both of these oncogenic γ-herpesviruses and that KSHV, surprisingly, relies on EBV for persistence in this model.

EBV and KSHV Tumorigenesis {#S3}
==========================

The above-discussed mortality is probably in part connected to the lymphomagenesis that can be observed in HIS mice after single EBV and EBV plus KSHV co-infection. After 5--6 weeks of infection with 10^5^ infectious particles of the B95-8 EBV, 20--30% of mice develop macroscopically visible tumors in various organs, including spleen, pancreas, kidney, liver, and lymph nodes ([@B16], [@B20], [@B21]). Tumor incidence does not seem to be significantly different in EBV-infected BLT mice ([@B18]). These are EBV latency III B cell tumors, which can be grown as EBV-transformed B cell lines *in vitro* after dissociation of the visible tumors (Figure [1](#F1){ref-type="fig"}) ([@B16], [@B29], [@B31]). The ability of HIS mice to develop B cell lymphomas has been used to query the role of different latent EBV antigens and lytic EBV replication in EBV-associated lymphomagenesis. Along these lines, the nuclear antigen 3B of EBV (EBNA3B) has been found to be deleted in a subset of EBV-associated DLBCLs in patients ([@B31], [@B32]). Accordingly, EBNA3B-deficient B95-8 EBV causes macroscopically visible tumors in 50% of HIS mice after 4 weeks of infection ([@B31]). These tumors are, interestingly, devoid of T cell infiltrates and transcriptome analysis of EBNA3B-deficient EBV-transformed B cell lines that were derived from tumors in HIS mice, and DLBCL patients demonstrated a loss of pro-inflammatory chemokine production ([@B31]). Restoration of CXCL10 expression in EBNA3A-deficient tumor cell lines resulted in T cell-mediated immune control *in vivo*. In addition, the transcriptome analysis revealed that EBNA3B-deficient EBV-transformed B cells of HIS mice were more similar to patient-derived DLBCL cell lines in their gene expression than LCLs that had been transformed with EBNA3B-deficient EBV *in vitro* ([@B31]). These findings established EBNA3B as a viral tumor suppressor by its control over pro-inflammatory chemokines.

![Tumorigenesis and immune control of Epstein--Barr virus (EBV) with and without Kaposi sarcoma-associated herpesvirus (KSHV) co-infection in mice with human immune system components (HIS mice). KSHV co-infection converts EBV-induced immunoblastic lymphoma into primary effusion lymphoma (PEL)-like tumors. EBV-associated immunoblastic lymphomas are restricted by cytotoxic lymphocytes in humanized mice, including CD4^+^ and CD8^+^ T cells, natural killer (NK) cells, NKT cells, and Vγ9Vδ2 T cells.](fimmu-09-00238-g001){#F1}

Furthermore, it was noted that loss of lytic EBV replication decreased the ability of infection to cause lymphomagenesis ([@B18]). This at first sight counterintuitive behavior, namely that cell-destructive lytic EBV infection should benefit B cell transformation and lymphoma growth, was suggested to result from a pro-inflammatory environment upon early, possibly abortive lytic EBV replication, but the responsible pro-inflammatory components have not been identified so far. Nevertheless, decreased lymphomagenesis by the B95-8 EBV virus that lacks the immediate early lytic transactivator BZLF1 was also observed in a second study ([@B20]), and the BZLF1 overexpressing virus induced the same amount of lymphomas, but these contained up to 30% of early, but not late lytic EBV antigen expression ([@B33]), confirming a possible role of abortive lytic replication in lymphomagenesis by EBV.

In the same way, KSHV co-infection with EBV increases lytic EBV replication and EBV-associated tumorigenesis ([@B29]). Interestingly, in this first small animal *in vivo* model of KSHV persistence, the developing tumors carry KSHV in one-third of EBV-infected lymphoma cells. This leads to an upregulation of gene expression that is associated with plasma cell differentiation, including the plasma cell fingerprint that is characteristic for PELs (Figure [1](#F1){ref-type="fig"}) ([@B34]). About 39% of KSHV and EBV double-infected mice with PEL-like tumors succumb to their disease after 1 month ([@B29]), while 25% of patients with PEL succumb to tumor progression within 4 months ([@B35]). Therefore, KSHV and EBV double-infection that leads to PEL formation causes significant mortality. Interestingly, double-infection of KSHV with the lytic EBV replication-deficient BZLF1 knockout strain of B95-8 abolishes the gain of lymphomagenesis upon infection with both viruses ([@B29]). Furthermore, early and late lytic EBV gene expression were observed at higher frequencies in KSHV and EBV double-infected lymphomas of patients than in a heterogenous groups of EBV single-infected lymphomas. In good agreement, lytic EBV replication inhibition with ganciclovir caused complete sustained PEL remission in a patient with EBV and KSHV double-positive lymphoma ([@B36]), but only transient improvement in a patient with KSHV single-positive PEL ([@B37]). Thus, HIS mice infections with EBV alone and KSHV co-infection have revealed an unexpected role for lytic EBV replication during virus-associated lymphomagenesis, which might be even diagnostically useful to predict the risk of EBV-associated malignancy development during immune suppression ([@B38]).

EBV- and KSHV-Specific Immune Control {#S4}
=====================================

Primary immunodeficiencies that predispose for EBV-associated pathologies point toward an essential role for cytotoxic lymphocytes in the immune control of this oncogenic γ-herpesvirus ([@B39], [@B40]). The respective mutations affect the perforin degranulation machinery, co-stimulatory receptors on cytotoxic lymphocytes and DNA binding proteins that are required for the differentiation of NK, NKT, γδT, and CD8^+^ αβ T cells. Much less is known about the protective immune responses against KSHV in humans, but the available information points to similar requirements as in the immune control of EBV ([@B41]).

Some of these cytotoxic lymphocyte compartments have been interrogated during EBV infection of HIS mice. These studies initially focused on T cell responses. In loss-of-function experiments, antibody-mediated depletion of all T cells or CD8^+^ and CD4^+^ T cells was found individually to increase EBV viral loads and associated lymphomagenesis upon infection (Figure [1](#F1){ref-type="fig"}) ([@B16], [@B33], [@B42]). Blocking of the co-stimulatory 2B4 receptor, which is compromised in one primary immunodeficiency (Duncan disease or XLP1) that predisposes for uncontrolled EBV infection, resulted in the loss of CD8^+^ T cell-mediated immune control and elevated viral loads as well as increased tumor frequency ([@B43]). In gain-of-function experiments, adoptive transfer of lytic EBV antigen-specific CD8^+^ T cells was able to further reduce the low level of lytic EBV replication upon B95-8 infection of HIS mice ([@B20]). Furthermore, late lytic EBV antigen and LCL differentiation-specific CD4^+^ T cells were able to lower viral loads in EBV-infected HIS mice ([@B44]). If human immune system reconstitution is performed by unseparated cord blood injection rather than differentiation from human hematopoietic progenitor cells, the established T cell compartment rather supports EBV-associated lymphomagenesis, even in the absence of viral oncogenes ([@B45], [@B46]). These cord blood T cells provide CD4^+^ T cell help for EBV-associated lymphomas ([@B45]). This T cell help can, however, be converted into immune control by antibody-mediated blocking of the inhibitory receptors PD-1 and CTLA-4 ([@B47]), presumably mimicking a T cell compartment that might resemble EBV-associated Hodgkin's lymphoma, a tumor entity that can be efficiently treated by check-point blockade immunotherapy ([@B48]). Thus, T cell-mediated immune control of EBV can be interrogated in HIS mice, and depending on the method of immune compartment reconstitution, immune compartments of healthy EBV carriers or patients with EBV-associated malignancies can be modeled.

In addition, innate lymphocyte compartments have also been interrogated for their contribution to immune control of EBV. NK cell depletion leads to elevated viral loads and tumor formation in EBV-infected HIS mice (Figure [1](#F1){ref-type="fig"}) ([@B21], [@B49]). Lytic EBV infection is primarily controlled by the early-differentiated NK cells of HIS mice, because infection with BZLF1 knockout EBV is not affected by NK cell depletion. These early-differentiated NK cells also expand in children with IM ([@B22]). It seems that further differentiated NK cells with HLA-haplotype-specific inhibitory receptors can be recruited to this response in mixed HLA-mismatched hematopoietic progenitor cell reconstitutions, which presumably allow allogeneic recognition of EBV-infected B cells of one donor by the further differentiation NK cells of the other donor ([@B49]). In addition to NK cells, adoptive transfer of CD8^+^ NKT and Vγ9Vδ2 T cells restricts EBV-associated lymphomas in HIS mice (Figure [1](#F1){ref-type="fig"}) ([@B50], [@B51]). Furthermore, Vγ9Vδ2 T cell activation with phosphoantigens results in improved immune control of successive EBV infection in HIS mice ([@B52]). Interestingly, innate and adaptive lymphocyte compartments seem to compensate each other, because loss of NK cell-mediated immune control leads to enhanced CD8^+^ T cell expansion during EBV infection of HIS mice. It will be interesting to elucidate which EBV infection programs are controlled by these different lymphocyte populations and which receptors on NK, NKT, and γδ T cells mediate EBV restriction *in vivo*. Stimulation of these cytotoxic lymphocyte compartments by vaccination could correct loss of EBV-specific immune control in patients with EBV-associated malignancies, but also teach us how to induce comprehensive cell-mediated immune control against tumors in general.

Conclusion and Outlook {#S5}
======================

While we are beginning to understand the protective lymphocyte compartments during EBV infection, their characterization for KSHV infection is in its infancy. Furthermore, we still have an incomplete understanding of how the comprehensive immune control by cytotoxic lymphocytes against EBV is initiated; even so, EBV is the prototypic viral pathogen that elicits CD8^+^ T cell lymphocytosis during symptomatic infection in IM patients. A detailed understanding of the characteristics of a comprehensive immune control by cytotoxic lymphocytes and the mechanisms that lead to its priming should guide us to develop vaccines to elicit such immune control, not only against EBV in patients with associated malignancies, but also tumors or badly controlled viral infections in general.
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